NetworkNewsBreaks – Heat Biologics, Inc. (NASDAQ: HTBX) Shares Climb following Presentation of Positive Immune Data on HS-410 Phase 2 Bladder Cancer Trial
Shares of Heat Biologics (NASDAQ: HTBX) are up 8% on news that the company presented immunological data from its phase 2 trial evaluating HS-410 either alone or in combination with BCG in patients with non-muscle invasive bladder cancer (NMIBC) at the 2017 Genitourinary Cancers Symposium. Researchers reported that HS-410, in combination with BCG, is generally well-tolerated, and that HS-410 activates CD8+ T cells and that these immune responders appear to have a lower recurrence rate than non-immune responders. Overall, this data strengthens support for the vaccine mechanism of action and clinical proof-of-concept of immune activation. “These data continue to support…